Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM (VANISH)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01912534 |
Recruitment Status :
Completed
First Posted : July 31, 2013
Last Update Posted : January 11, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertrophic Cardiomyopathy | Drug: Valsartan Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 211 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM |
Actual Study Start Date : | March 2014 |
Actual Primary Completion Date : | July 2019 |
Actual Study Completion Date : | July 2019 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Valsartan
Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
|
Drug: Valsartan
40, 80 and 160 mg tablets of Valsartan
Other Name: Diovan Drug: Placebo During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
Other Name: Matching Placebo pills |
Placebo Comparator: Placebo
Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
|
Drug: Valsartan
40, 80 and 160 mg tablets of Valsartan
Other Name: Diovan Drug: Placebo During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
Other Name: Matching Placebo pills |
- Composite z-score [ Time Frame: 2 years ]Composite z-score which is the average of 9 change-scores of: serum NTproBNP, serum high-sensitivity cardiac troponin, left ventricular (LV) mass, left atrial (LA) volume, LV end diastolic volume, LV end systolic volume, maximal LV wall thickness, echo E' velocity, echo S' velocity
- z-score serum NTproBNP [ Time Frame: 2 years ]Z-score for the 2 year change for serum NTproBNP
- z-score high sensitivity cardiac troponin [ Time Frame: 2 years ]Z-score for the 2 year change for high-sensitivity cardiac troponin
- z-score LV mass [ Time Frame: 2 years ]Z-score for the 2 year change in LV Mass
- z-score LA volume [ Time Frame: 2 years ]Z-score for the 2 year change in LA Volume
- z-score LV end diastolic volume [ Time Frame: 2 years ]Z-score for the 2 year change in LV end diastolic volume
- z-score LV end systolic volume [ Time Frame: 2 years ]Z-score for the 2 year change in LV end systolic volume
- z-score maximal LV wall thickness [ Time Frame: 2 years ]Z-score for the 2 year change in Maximal LV wall thickness
- z-score echo E' velocity [ Time Frame: 2 years ]Z-score for the 2 year change in echo E' velocity
- z-score echo S' velocity [ Time Frame: 2 years ]Z-score for the 2 year change in echo S' velocity
- Binary indicator of success or failure [ Time Frame: 2 years ]Success defined as an improvement at 2 years in any of the following: serum NTproBNP, serum high-sensitivity troponin, LV Mass, LA Volume, LV end diastolic volume, LV end systolic volume, Maximal LV wall thickness, echo E' velocity, or echo S' velocity
- Safety of valsartan as assessed by incidence of adverse events [ Time Frame: 2 years ]Safety of valsartan as assessed by incidence of adverse events

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 8 Years to 45 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
1. All subjects must have a Pathogenic or Likely Pathogenic HCM Sarcomere Mutation
a. The following categories of mutations are considered acceptable for subjects who have previously undergone clinical genetic testing. If results are ambiguous, they will be reviewed by the Clinical Coordinating Center to determine eligibility.
- Laboratory for Molecular Medicine (Pathogenic, Likely Pathogenic)
- Transgenomics/ PGXHealth (Class I)
- GeneDx (Disease causing; Variant; likely disease-causing; Published, disease-causing mutation; Novel, likely disease-causing, mutation)
- Correlagen (Associated; Probably Associated)
Group 1 (Overt HCM Cohort)
- LV wall thickness ≥12 mm and ≤25 mm or z score ≥3 and ≤18 as determined by rapid assessment by the echocardiographic core laboratory
- NYHA functional class I or II; no perceived or only slight limitations in physical activities
- No resting or provokable LV obstruction (peak gradient ≤ 30 mmHg) on clinically-obtained Exercise Tolerance Test (ETT)-echo within the past 24 months or transthoracic echo with Valsalva maneuver within the past 12 months
- Age 8-45 years
- Able to attend follow-up appointments, complete all study assessments, and provide written informed consent
Group 2 (Preclinical HCM Cohort (G+/LVH-))
- LV Wall Thickness <12 mm and z score <3 , as determined by rapid assessment by the echocardiographic core laboratory
- Age 10-25 years
- E' z score ≤ -1.5 OR ECG abnormalities other than NSSTW changes (Q waves, T wave inversion, repolarization changes) OR LV wall thickness z-score 1.5-2.9 combined with LV thickness to dimension ratio ≥0.19 (as determined by rapid assessment by the echocardiographic core laboratory)
- Able to attend follow-up appointments, complete all study assessments, and provide written informed consent
Subject Exclusion Criteria
- Contraindication to angiotensin receptor blocker (ARB) administration, including impaired renal function, hyperkalemia (serum K>5.0 mmol/L), prior history of angioedema
- Medical conditions associated with increased collagen turnover that may confound interpretation of biomarkers of collagen synthesis (liver, pulmonary or renal fibrosis, inflammatory states, cancer, trauma or surgery within 6 months of enrollment)
- Concomitant use of Spironolactone, Lithium, or Aliskiren, ARB or ACE-inhibitors. If these drugs are in active use but not necessary for medical care, they may be discontinued and baseline studies can be performed after a 2-week washout period.
- Pregnant or breastfeeding females - Females of childbearing potential with no effective contraceptive method (including abstinence)
- Uncontrolled systemic HTN [persistent SBP>160 and/or DBP>90 in adult or equivalent in children (e.g., SBP>99th or DBP>95th percentile for sex, age, and height centile based on the American Academy of Pediatrics normal values)]
- Obstructive physiology, defined by resting, Valsalva-provoked or exercise-induced gradient >30mmHg within the past 24 months
- Prior septal myectomy or alcohol septal ablation
- Known, suspected, or symptomatic coronary artery disease or evidence of prior myocardial infarction based on symptoms or cardiac imaging
- More than mild valvular heart disease or clinically significant congenital heart disease. Allowable conditions include bicuspid aortic valve without clinically significant stenosis or regurgitation; spontaneously closed ventricular septal defects; patent foramen ovale, small (≤ 2 mm) restrictive ventricular septal defects with normal ventricular size, and other minor defects that are considered allowable after [review and consensus by participating pediatric cardiologists, overall study PI and] adjudication by the echocardiographic core laboratory.
- Left ventricular ejection fraction (LVEF) <55%
- Concomitant medical conditions that would preclude performance of or confound interpretation of echocardiography, exercise testing, or CMR (e.g., renal insufficiency, lung disease, orthopedic/rheumatologic conditions, atrial fibrillation)
- Secondary prevention implantable cardioverter-defibrillator device (ICD; primary prevention ICDs without a history of appropriate therapy, including shock or ATP, are allowable).
- Prior treatment or hospitalization for symptomatic heart failure
- Participation in a clinical trial (except observational studies) involving investigational medications within the previous 30 days.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01912534
United States, California | |
Stanford University | |
Stanford, California, United States, 94305 | |
United States, Colorado | |
University of Colorado | |
Aurora, Colorado, United States, 80045 | |
United States, Illinois | |
University of Chicago | |
Chicago, Illinois, United States, 60637 | |
United States, Maryland | |
Johns Hopkins University | |
Baltimore, Maryland, United States, 21287 | |
United States, Massachusetts | |
Brigham & Women's Hospital | |
Boston, Massachusetts, United States, 02115 | |
Children's Hospital Boston | |
Boston, Massachusetts, United States, 02115 | |
United States, Michigan | |
University of Michigan | |
Ann Arbor, Michigan, United States, 48109 | |
United States, Missouri | |
Washington University School Medicine | |
Saint Louis, Missouri, United States, 63110 | |
United States, Ohio | |
Cinncinnati Children's Hospital Medical Center | |
Cincinnati, Ohio, United States, 45229 | |
Cleveland Clinic Foundation | |
Cleveland, Ohio, United States, 44195 | |
United States, Pennsylvania | |
Children's Hospital of Philadelphia | |
Philadelphia, Pennsylvania, United States, 19104 | |
University of Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, Tennessee | |
Vanderbilt University | |
Nashville, Tennessee, United States, 37232 | |
Canada, Ontario | |
Toronto General Hospital | |
Toronto, Ontario, Canada, M4W3S5 | |
Toronto Sick Kids | |
Toronto, Ontario, Canada, M5G1X8 |
Principal Investigator: | Carolyn Y. Ho, MD | Brigham and Women's Hospital |
Responsible Party: | HealthCore-NERI |
ClinicalTrials.gov Identifier: | NCT01912534 |
Other Study ID Numbers: |
VANISH 5P50HL112349 ( U.S. NIH Grant/Contract ) |
First Posted: | July 31, 2013 Key Record Dates |
Last Update Posted: | January 11, 2021 |
Last Verified: | April 2020 |
Sarcomere Mutations |
Cardiomyopathies Cardiomyopathy, Hypertrophic Heart Diseases Cardiovascular Diseases Aortic Stenosis, Subvalvular Aortic Valve Stenosis Aortic Valve Disease |
Heart Valve Diseases Valsartan Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action |